(RPRX) Royalty Pharma - Ratings and Ratios
Royalties, Cancer, Rare Disease, Diabetes, Infectious
RPRX EPS (Earnings per Share)
RPRX Revenue
Description: RPRX Royalty Pharma
Royalty Pharma plc is a prominent player in the biopharmaceutical industry, operating as a buyer of royalties and a funder of innovation. With a diverse portfolio of approximately 35 marketed therapies and 14 development-stage product candidates, the company addresses various therapeutic areas, including rare disease, cancer, and neuroscience. This strategic focus enables Royalty Pharma to capitalize on emerging trends and technologies in the industry.
Key performance indicators (KPIs) that can be used to evaluate Royalty Pharmas success include revenue growth, royalty income as a percentage of total revenue, and the number of new product candidates added to their portfolio. Additionally, metrics such as return on equity (RoE) of 16.19% and a forward price-to-earnings (P/E) ratio of 12.21 indicate a relatively strong financial performance. The companys market capitalization of $20.45 billion also suggests a significant presence in the industry.
From a strategic perspective, Royalty Pharmas business model allows it to mitigate some of the risks associated with biopharmaceutical development by diversifying its portfolio across multiple therapeutic areas and product candidates. The companys ability to fund innovation and acquire royalties also positions it to capitalize on emerging opportunities in the industry. As the biopharmaceutical landscape continues to evolve, Royalty Pharmas adaptability and focus on innovation will be crucial to its long-term success.
To further analyze Royalty Pharmas potential, one could examine its royalty income streams, the stage of development for its product candidates, and the competitive landscape within its target therapeutic areas. By assessing these factors, investors and analysts can gain a more comprehensive understanding of the companys growth prospects and potential risks, ultimately informing more informed investment decisions.
RPRX Stock Overview
| Market Cap in USD | 20,948m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 1993-03-25 |
RPRX Stock Ratings
| Growth Rating | 19.6% |
| Fundamental | 51.3% |
| Dividend Rating | 68.0% |
| Return 12m vs S&P 500 | 8.55% |
| Analyst Rating | 4.25 of 5 |
RPRX Dividends
| Dividend Yield 12m | 2.59% |
| Yield on Cost 5y | 2.36% |
| Annual Growth 5y | 22.87% |
| Payout Consistency | 100.0% |
| Payout Ratio | 20.4% |
RPRX Growth Ratios
| Growth Correlation 3m | 75.2% |
| Growth Correlation 12m | 87.2% |
| Growth Correlation 5y | -66.9% |
| CAGR 5y | -0.45% |
| CAGR/Max DD 5y | -0.01 |
| Sharpe Ratio 12m | 1.10 |
| Alpha | 23.78 |
| Beta | 0.031 |
| Volatility | 22.03% |
| Current Volume | 2994k |
| Average Volume 20d | 2994k |
| Stop Loss | 34.9 (-3%) |
| Signal | 1.31 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (1.02b TTM) > 0 and > 6% of Revenue (6% = 138.3m TTM) |
| FCFTA 0.13 (>2.0%) and ΔFCFTA -1.64pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 13.61% (prev 102.9%; Δ -89.34pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.13 (>3.0%) and CFO 2.47b > Net Income 1.02b (YES >=105%, WARN >=100%) |
| Net Debt (7.39b) to EBITDA (872.9m) ratio: 8.46 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.26 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (562.3m) change vs 12m ago -5.80% (target <= -2.0% for YES) |
| Gross Margin 99.93% (prev 57.84%; Δ 42.08pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 12.82% (prev 12.67%; Δ 0.14pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 2.76 (EBITDA TTM 872.9m / Interest Expense TTM 266.2m) >= 6 (WARN >= 3) |
Altman Z'' 1.05
| (A) 0.02 = (Total Current Assets 1.52b - Total Current Liabilities 1.21b) / Total Assets 18.32b |
| (B) 0.12 = Retained Earnings (Balance) 2.22b / Total Assets 18.32b |
| (C) 0.04 = EBIT TTM 735.1m / Avg Total Assets 17.99b |
| (D) 0.25 = Book Value of Equity 2.22b / Total Liabilities 8.82b |
| Total Rating: 1.05 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 51.32
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 8.72% = 4.36 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 1.26 = 1.76 |
| 5. Debt/Ebitda 9.17 = -2.50 |
| 6. ROIC - WACC -1.30% = -1.62 |
| 7. RoE 15.20% = 1.27 |
| 8. Rev. Trend -12.53% = -0.63 |
| 9. Rev. CAGR 0.33% = 0.04 |
| 10. EPS Trend 25.70% = 0.64 |
| 11. EPS CAGR -49.88% = -2.50 |
What is the price of RPRX shares?
Over the past week, the price has changed by -0.94%, over one month by -2.88%, over three months by +10.90% and over the past year by +26.97%.
Is Royalty Pharma a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of RPRX is around 37.82 USD . This means that RPRX is currently overvalued and has a potential downside of 5.11%.
Is RPRX a buy, sell or hold?
- Strong Buy: 4
- Buy: 2
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the RPRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 43.3 | 20.3% |
| Analysts Target Price | 41.5 | 15.4% |
| ValueRay Target Price | 40.7 | 13.1% |
Last update: 2025-08-20 02:48
RPRX Fundamental Data Overview
CCE Cash And Equivalents = 645.1m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 15.6856
P/E Forward = 11.9048
P/S = 9.0869
P/B = 2.4462
P/EG = 3.1244
Beta = 0.543
Revenue TTM = 2.31b USD
EBIT TTM = 735.1m USD
EBITDA TTM = 872.9m USD
Long Term Debt = 7.00b USD (from longTermDebt, last quarter)
Short Term Debt = 999.4m USD (from shortTermDebt, last quarter)
Debt = 8.00b USD (Calculated: Short Term 999.4m + Long Term 7.00b)
Net Debt = 7.39b USD (from netDebt column, last quarter)
Enterprise Value = 28.31b USD (20.95b + Debt 8.00b - CCE 645.1m)
Interest Coverage Ratio = 2.76 (Ebit TTM 735.1m / Interest Expense TTM 266.2m)
FCF Yield = 8.72% (FCF TTM 2.47b / Enterprise Value 28.31b)
FCF Margin = 107.1% (FCF TTM 2.47b / Revenue TTM 2.31b)
Net Margin = 44.26% (Net Income TTM 1.02b / Revenue TTM 2.31b)
Gross Margin = 99.93% ((Revenue TTM 2.31b - Cost of Revenue TTM 1.65m) / Revenue TTM)
Tobins Q-Ratio = 12.73 (Enterprise Value 28.31b / Book Value Of Equity 2.22b)
Interest Expense / Debt = 0.86% (Interest Expense 68.7m / Debt 8.00b)
Taxrate = 35.46% (from yearly Income Tax Expense: 472.0m / 1.33b)
NOPAT = 474.4m (EBIT 735.1m * (1 - 35.46%))
Current Ratio = 1.26 (Total Current Assets 1.52b / Total Current Liabilities 1.21b)
Debt / Equity = 1.26 (Debt 8.00b / last Quarter total Stockholder Equity 6.35b)
Debt / EBITDA = 9.17 (Net Debt 7.39b / EBITDA 872.9m)
Debt / FCF = 3.24 (Debt 8.00b / FCF TTM 2.47b)
Total Stockholder Equity = 6.71b (last 4 quarters mean)
RoA = 5.57% (Net Income 1.02b, Total Assets 18.32b )
RoE = 15.20% (Net Income TTM 1.02b / Total Stockholder Equity 6.71b)
RoCE = 5.36% (Ebit 735.1m / (Equity 6.71b + L.T.Debt 7.00b))
RoIC = 3.29% (NOPAT 474.4m / Invested Capital 14.42b)
WACC = 4.59% (E(20.95b)/V(28.95b) * Re(6.13%)) + (D(8.00b)/V(28.95b) * Rd(0.86%) * (1-Tc(0.35)))
Shares Correlation 5-Years: -10.0 | Cagr: -1.90%
Discount Rate = 6.13% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 78.58% ; FCFE base≈2.55b ; Y1≈2.60b ; Y5≈2.87b
Fair Price DCF = 117.0 (DCF Value 50.60b / Shares Outstanding 432.3m; 5y FCF grow 1.81% → 3.0% )
Revenue Correlation: -12.53 | Revenue CAGR: 0.33%
Rev Growth-of-Growth: 6.33
EPS Correlation: 25.70 | EPS CAGR: -49.88%
EPS Growth-of-Growth: 20.48
Additional Sources for RPRX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle